NASDAQ:CERT Certara Q3 2026 Earnings Date & Estimates $9.20 +0.56 (+6.42%) As of 02:30 PM Eastern This is a fair market value price provided by Massive. Learn more. Certara is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 5:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call5:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Certara in Q3 2026Certara is expected to post earnings of $0.09 per share on revenue of $92.59 million. In the same quarter a year earlier Certara reported $0.14 per share on revenue of $104.62 million. Certara last reported on August 4, 2026, posting $0.08 per share and missing the $0.0893 consensus estimate. Certara has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.09Expected Revenue$92.59 millionPrior-Year EPS$0.14Prior-Year Revenue$104.62 millionExpected EPS Growth-35.7%Expected Revenue Growth-11.5%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.08 (Missed by -$0.0093)Last Quarter Revenue$93.27 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Certara Q3 2026 Earnings FAQ When does Certara report Q3 2026 earnings? Certara (NASDAQ:CERT) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. What time is Certara's Q3 2026 earnings call? Certara's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Certara? Analysts expect Certara to post earnings of $0.09 per share for Q3 2026. How much revenue is Certara expected to report? The consensus revenue estimate for Certara is $92.59 million for Q3 2026. Certara Earnings HeadlinesCertara (NASDAQ:CERT) Stock Gets Price Target Bump from BarclaysOctober 9 at 1:55 AM | americanbankingnews.comComparing Health Catalyst (NASDAQ:HCAT) and Certara (NASDAQ:CERT)October 6 at 4:29 AM | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 9 at 1:00 AM | Stansberry Research (Ad)Contrasting Certara (NASDAQ:CERT) & OptimizeRx (NASDAQ:OPRX)October 5, 2026 | americanbankingnews.comUBS downgrades Certara to neutral from buySeptember 30, 2026 | msn.comUBS Downgrades Certara to Neutral From Buy, $10 Price TargetSeptember 30, 2026 | marketscreener.comMSee More Certara Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Certara? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Certara and other key companies, straight to your email. Email Address About CertaraCertara (NASDAQ:CERT) (NASDAQ:CERT) provides software and technology-enabled services for the biopharmaceutical industry. The company helps drug developers use regulatory science, data analysis, and modeling and simulation to support decisions throughout the research, development, and commercialization lifecycle. Its offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial design, patient and disease modeling, regulatory submissions, and real-world data analysis. Certara also provides consulting and scientific services, including regulatory strategy, model-informed drug development, biostatistics, pharmacovigilance, and medical and regulatory writing. Certara serves pharmaceutical and biotechnology companies, academic and research institutions, and regulatory agencies internationally. The company was founded in 2008 through the combination of consulting and technology businesses focused on drug development and became a publicly traded company on the Nasdaq in 2020. Its operations and customer base span North America, Europe, and Asia-Pacific.View Certara ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
